Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Sorrento's 158% Spike Could Be Just The Beginning

The stock of Sorrento Therapeutics soared more than 150% in trading on Friday after announcing a potentially significant development on the COVID-19 front.

Seizing The Day On Sorrento Therapeutics

Sorrento Therapeutics (SRNE) news for Friday concerning a possible cure for the novel coronavirus has SRNE stock soaring.

Sorrento Therapeutics News: SRNE Stock Skyrockets 172% on Claims of ‘COVID-19 Cure’

Shares of Sorrento Therapeutics Inc. SRNE, +137.40% blasted 153% higher on very heavy volume in afternoon trading Friday, putting it on track to close at a near 2-year high, after the biopharmaceutical company provided an upbeat assessment of the results of a preclinical experiment of its COVID-19 virus antibody.

Sorrento Therapeutics' stock soars on massive volume after upbeat report on COVID-19 antibody experiment

The company might have found a way to end the ongoing coronavirus pandemic.

Why Sorrento Therapeutics Is Skyrocketing Today

Sorrento Therapeutics Inc (NASDAQ: SRNE), which received a takeover bid early this year, is in the spotlight yet again.

Sorrento Therapeutics Rips Higher On Reports Of Possible Coronavirus Antibody

Sorrento Therapeutics reportedly claimed Friday its experimental coronavirus treatment is a cure for Covid-19. Hologic also inched up after gaining an EUA for a second coronavirus test.

Covid Report: Sorrento Therapeutics Claims It Has A Coronavirus Cure

Therapeutics company Sorrento has made what it believes cold be a breakthrough in potential treatment of SARS-CoV-2, the virus that leads to COVID-19. The company released details its preclinical research on Friday, announcing that it has found an antibody that provides “100% inhibition of SARS-CoV-2 virus infection of healthy cells after four days incubation.

Sorrento finds a coronavirus antibody that blocks viral infection 100% in preclinical lab experiments

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Shares of Sorrento Therapeutics Inc. SRNE, +8.83% gained 8.9% in trading on Friday after the company said it plans to develop an antibody cocktail treatment for patients at risk or with new infections of COVID-19 in partnership with Mount Sinai Health System in New York.

Sorrento's stock jumps on antibody plans with Mount Sinai Health System

Sorrento Therapeutics and Mount Sinai Health System in New York City have joined forces to develop an antibody cocktail they hope will shield against Covid-19 infection for up to two months.

Sorrento Therapeutics and Mount Sinai join forces to develop Covid-19 antibody shield

SAN DIEGO, April  02, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. On April 2, 2020, Celularity announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for the use of its proprietary CYNK-001 in adults with COVID-19. Celularity also announced that it will immediately commence a Phase I/II clinical study including up to 86 patients with COVID-19.

SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS

SAN DIEGO, March  31, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. Dr. Slobodan Paessler, DVM, Ph.D., John S. Dunn Distinguished Chair in Biodefense and scientific director of the Animal Biosafety Laboratory 3 at the Galveston National Laboratory, will be supervising the research.

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

SAN DIEGO, March  25, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics Evaluation and Research under IND#019724 regarding the required IND-enabling studies, CMC (chemistry, manufacturing and controls), clinical protocol and end-points for potential accelerated approval. Upon receiving guidance from the FDA, Sorrento intends to submit a full package for an IND filing that would enable human clinical trials to start as soon as possible.

Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program

SAN DIEGO, March  24, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK, “Mabpharm”), for the clinical development and commercialization of the ACE-MAB fusion protein (Sorrento’s product code name STI-4920 and Mabpharm’s product code name CMAB020) for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. Mabpharm has generated a fusion protein (CMAB020) that binds to the spike protein of the SARS-CoV-2 virus.

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

Collaboration to leverage synergies between Monoclonal Antibody and Non-Viral Gene Delivery Platforms Collaboration to leverage synergies between Monoclonal Antibody and Non-Viral Gene Delivery Platforms

SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19

Sorrento Therapeutics Inc (NASDAQ: SRNE), which is being touted as a takeover target, announced Friday it's working on potential preventative treatment for SARS-CoV-2, the virus that causes COVID-19.

Sorrento Plans Preclinical Testing Of 'COVIDTRAP' Protein To Treat New Coronavirus

SAN DIEGO, March  20, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has produced a preclinical batch of the STI-4398 (COVIDTRAP) protein to immediately commence testing its neutralization and blocking activity in preventing SARS-CoV-2 virus from infecting ACE2-expressing cells.

SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

Earnings Preview: Sorrento Therapeutics (SRNE) Q4 Earnings Expected to Decline

SAN DIEGO, Feb.  27, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced that an interim analysis of an ongoing Phase 1b study of resiniferatoxin (RTX) administered via epidural route in patients with intractable cancer pain has generated positive data. The study is completing enrollment of an additional 25 ug expansion dose cohort. Based on full study results a dose will be selected for RTX to proceed to Phase 3 pivotal trials in patients with advanced cancer pain.

Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

SAN DIEGO, Feb.  21, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thursday Feb 27 at 11:00-11:25 AM (Presentation Room Adams).

Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference

The pharmaceutical stock soared after being approached for an acquisition, but has tanked in the weeks since management announced it has declined the offer.

Here's Why Sorrento Therapeutics Shares Jumped 13.3% in January

The companies have jumped into the fray against the 2019-nCoV outbreak.

Sorrento Therapeutics and Celularity Aim to Adapt Natural Killer Cell Therapy to Treat Coronavirus

SAN DIEGO and WARREN, N.J., Jan.  29, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. The objective of the collaboration is to expand the therapeutic use of Celularity's CYNK-001, an allogeneic, off-the-shelf, placental-derived Natural Killer (NK) cell therapy, to the treatment and prevention of coronavirus infections.

Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection

Sorrento's Share Price Woes Are In Remission, But The Long-Term Prognosis Is Far From Certain

News for Sorrento Therapeutics Inc Stock (SRNE)